A Phase 3 Study Testing Dexmedetomidine for Treating Electrical Storm in Intensive Care Patients

What this Trial Is About

Researchers are investigating the potential benefit of using the sedative medication dexmedetomidine in the acute treatment of patients experiencing electrical storm, a life-threatening condition characterized by recurrent ventricular arrhythmias. This multi-center, double-blinded, placebo-controlled, randomized trial aims to evaluate whether early sedation with dexmedetomidine can improve outcomes for these patients in intensive care units. Electrical storm involves autonomic dysfunction and high sympathetic tone, which may worsen arrhythmias, and current treatments include anti-arrhythmic drugs and sedatives. Participants will be randomly assigned to receive either dexmedetomidine or a placebo normal saline as part of their initial intensive care treatment. Those receiving dexmedetomidine will start at 0.3 mcgkghr and be titrated up to 1.0 mcgkghr or the maximum tolerated dose. Treatment will continue for approximately 48 hours, followed by a weaning phase, both guided by the treating physician. The placebo group will follow a similar dosing and weaning schedule using saline. During the study, participants will be monitored for outcomes including in-hospital death and ventricular arrhythmias requiring treatment after starting the study drug. The primary outcome combines these events during the hospital stay, which typically lasts about two weeks. Secondary outcomes include cardiac arrest, renal failure, intubation, length of ICU and hospital stay, and need for mechanical support. Safety and effectiveness will be assessed through regular evaluations during the hospitalization period.

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm